<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406392</url>
  </required_header>
  <id_info>
    <org_study_id>SUBMISO</org_study_id>
    <nct_id>NCT01406392</nct_id>
  </id_info>
  <brief_title>Sublingual Misoprostol for Induction of Labor</brief_title>
  <acronym>SUBMISO</acronym>
  <official_title>Sublingual Misoprostol 12,5 mcg Versus Vaginal Misoprostol 25 mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Fernando Figueira Integral Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternidade Escola Assis Chateaubriand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Professor Fernando Figueira Integral Medicine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effectiveness and safety of a sublingual misoprostol
      12,5 mcg with vaginal misoprostol 25 mcg for induction of labour with an alive and term
      fetus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several methods for induction of labour are available. However, the most effective and with
      less frequency of adverse effects is still unknown. Vaginal misoprostol has been used
      frequently to induce labour but other routes of administrations have been proposed, such as
      oral and sublingual. The purpose of this study is to compare effectiveness and safety of
      sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg administration for induction
      of labour with an alive and term fetus. A randomized controlled double-blind trial will be
      carried in two hospitals: Instituto de Medicina Integral Prof. Fernando Figueira and
      Universidade Federal do Ceará and Instituto de Saúde Elpídio de Almeida, from July 2014 to
      November 2016. A total of 150 patients must be enrolled. Inclusion criteria are: a)
      indication for labour induction; b) term pregnancy with alive fetus; Bishop score less than
      six. Exclusion criteria are: a) previous uterine scar; b) nonvertex presentation; c)
      non-reassuring fetal status; d) fetal anomalies; e) fetal growth restriction; f) genital
      bleeding; g) tumors, malformations and/or ulcers of vulva, perineum or vagina. They will be
      randomized to receive a sublingual misoprostol 12,5 mcg with vaginal placebo tablet or
      sublingual placebo with vaginal misoprostol 25 mcg tablet. Vaginal tablets will have 25mcg of
      misoprostol or placebo. Sublingual tablet will have 12,5mcg or placebo. Vaginal misoprostol
      or placebo tablets will be administered for each six hours until the maximum dose of 200mcg
      or eight tablets. Primary outcome will be the frequency of tachysystole. Secondary outcomes
      will be vaginal delivery within 24 hours, hyperstimulation syndrome, cesarean section, severe
      neonatal morbidity or perinatal death, serious maternal morbidity or maternal death, need of
      oxytocin for augmentation of labour, number of misoprostol doses needed to bring on labour,
      interval from first dose to labour and first dose to delivery, failed induction, uterine
      rupture, need of labour analgesia, instrumental delivery, side effects, maternal death,
      meconium, non-reassuring fetal heart rate, Apgar scores less than seven at 1st and 5th
      minutes, admission at neonatal intensive care unit, neonatal encephalopaty, perinatal death
      and women not satisfied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of taquissistoly</measure>
    <time_frame>48 hours</time_frame>
    <description>during 48 hours the presence of taquissistoly will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperstimulation Syndrome</measure>
    <time_frame>48 hours</time_frame>
    <description>during 48 hours the presence of hyperstimulation syndrome will be observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the cervix at 12 and 24 hours</measure>
    <time_frame>12 and 24 hours</time_frame>
    <description>changes in the cervix</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure to achieve vaginal delivery within 12 and 24 hours</measure>
    <time_frame>12 and 24 hours</time_frame>
    <description>failure to achieve vaginal delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the mother's preferred route of administration</measure>
    <time_frame>after 48 hours</time_frame>
    <description>Ask to mother what route of administratios was the best for her</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time between the first dose and the onset of labour and delivery</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the time between the first dose and the onset of labour and delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of labour</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the time of duration of labour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for oxytocin</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the use of oxytocin during the labour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failed induction of labour</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the faliled induction of labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caesarean section and the indications for this procedure</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the number of Caesarean section and the indications for this procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for epidural anaesthesia</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the need for epidural anaesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete if occurred any case of maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death</measure>
    <time_frame>48 hours</time_frame>
    <description>to avaluete severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>meconium in the amniotic fluid</measure>
    <time_frame>48 hours</time_frame>
    <description>to avaluete meconium in the amniotic fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-reassuring foetal heart rate</measure>
    <time_frame>48 hours</time_frame>
    <description>non-reassuring foetal heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one- and five-minute Apgar scores &lt;7</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete one- and five-minute Apgar scores &lt;7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission of the newborn to a neonatal intensive care unit</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete admission of the newborn to a neonatal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for neonatal resuscitation</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete the need for neonatal resuscitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.</measure>
    <time_frame>after 48 hours</time_frame>
    <description>to avaluete severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Labor</condition>
  <condition>Induced</condition>
  <arm_group>
    <arm_group_label>Sublingual Misoprostol 12,5mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol 25 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 25mcg</intervention_name>
    <description>Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.</description>
    <arm_group_label>Vaginal Misoprostol 25 mcg</arm_group_label>
    <other_name>Prostokos Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Misoprostol</intervention_name>
    <description>Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets</description>
    <arm_group_label>Sublingual Misoprostol 12,5mcg</arm_group_label>
    <other_name>Prostokos</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for labour induction

          -  Term pregnancy with alive fetus

          -  Bishop score less than six

        Exclusion Criteria:

          -  Previous uterine scar

          -  Nonvertex presentation

          -  Non-reassuring fetal status

          -  Fetal anomalies

          -  Fetal growth restriction

          -  Genital bleeding

          -  Tumors, malformations and/or ulcers of vulva, perineum or vagina
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Professor Fernando Figueira (IMIP)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>September 15, 2019</last_update_submitted>
  <last_update_submitted_qc>September 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Professor Fernando Figueira Integral Medicine Institute</investigator_affiliation>
    <investigator_full_name>Daniele Sofia de Moraes Barros Gattas</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Sublingual</keyword>
  <keyword>Induced</keyword>
  <keyword>Labor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After publication in scientific journal</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

